These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15539935)

  • 1. Therapeutic targeting of prostate cancer.
    Cress AE; Mohla S
    Cancer Biol Ther; 2004 Oct; 3(10):1028-30. PubMed ID: 15539935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer.
    Naitoh J; Witte O; Belldegrun A
    Cancer Res; 1998 Jul; 58(13):2895-900. PubMed ID: 9661908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Hawley JE; Adelaiye-Ogala R; Calais J; Nappi L; Parikh R; Seibert TM; Wasmuth EV; Wei XX; Pienta KJ; Soule HR
    Prostate; 2023 Feb; 83(3):207-226. PubMed ID: 36443902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
    Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.
    Slovin SF; Livingston PO; Rosen N; Sepp-Lorenzino L; Kelly WK; Mendelsohn J; Scher HI
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):41-8. PubMed ID: 8996585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
    Miyahira AK; Morris M; Soule HR;
    Prostate; 2017 Feb; 77(3):245-254. PubMed ID: 27800631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Kamran SC; Jamaspishvili T; Marshall CH; Maxwell KN; Parolia A; Zorko NA; Pienta KJ; Soule HR
    Prostate; 2024 Aug; 84(11):993-1015. PubMed ID: 38682886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR
    Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Den RB; Carlo MI; de Leeuw R; Hope TA; Karzai F; McKay RR; Salami SS; Simons JW; Pienta KJ; Soule HR
    Prostate; 2019 Feb; 79(3):244-258. PubMed ID: 30381857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database.
    Lai MW; Klein-Schwartz W; Rodgers GC; Abrams JY; Haber DA; Bronstein AC; Wruk KM
    Clin Toxicol (Phila); 2006; 44(6-7):803-932. PubMed ID: 17015284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.
    Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y
    Curr Cancer Drug Targets; 2010 May; 10(3):287-306. PubMed ID: 20370680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targets for metastatic prostate cancer.
    Timme TL; Satoh T; Tahir SA; Wang H; Teh BS; Butler EB; Miles BJ; Amato RJ; Kadmon D; Thompson TC
    Curr Drug Targets; 2003 Apr; 4(3):251-61. PubMed ID: 12643475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center.
    Lee DH; Jung HB; Lee SH; Rha KH; Choi YD; Hong SJ; Yang SC; Chung BH
    Jpn J Clin Oncol; 2012 Nov; 42(11):1079-85. PubMed ID: 22988037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions.
    Pantuck AJ; Zisman A; Belldegrun AS
    World J Urol; 2000 Apr; 18(2):143-7. PubMed ID: 10854150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12].
    Brent H
    Urol Oncol; 2016 May; 34(5):247-8. PubMed ID: 25990613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.